Read our latest' SAMHD! expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma. From Waaqo Daddacha, David S. Yu and coworkers Winship Cancer Institute of Emory University Augusta University academic.oup.com/narcancer/arti…

Read our latest: expression level of bifunctional glycosylase/AP lyase NTHL1 controls cisplatin sensitivity in lung epithelial and NSCLC cells. From Anirban Kar, Natalya Degtyareva, Paul Doetsch @niehs academic.oup.com/narcancer/arti…

Read our latest: Dysregulation of the ORigin FIring Under Stress (ORFIUS) complex may promote high grade serous ovarian cancer survival after DNA damage. From the Sarah J. Hill lab Dana-Farber academic.oup.com/narcancer/arti…

Read our latest: linking metabolic reprogramming to rewiring of RNA methylation in renal cell carcinoma. From Pedro Batista lab Pedro Batista National Cancer Institute . academic.oup.com/narcancer/arti…

Sad to hear of this loss to the community.

New in NAR Cancer. A resource to guide functional studies: a compendium of long noncoding RNAs associated with tumor, immune, or stromal cells in pancreatic cancer. From @ChrisMaher and coworkers. Washington University in St. Louis Siteman Cancer Center #lncrnas #bioinformatics . academic.oup.com/narcancer/arti…

Read our latest: Proteasome dysfunction increases APOBEC3A abundance, potentially increasing genetic heterogeneity and thereby influencing therapeutic responses. From Margo Coxon, Steven A Roberts and coworkers UVM Cancer Center academic.oup.com/narcancer/arti…

Read our latest: CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via HR. The findings of this study may open additional clinical avenues to improve outcomes. From Blueprint Medicines academic.oup.com/narcancer/arti…

Avoid pitfalls and accelerate discovery. Comprehensive guide to databases for cancer target evaluation - with examples - from Cancer Research Horizons

NAR Cancer thanks its editors, authors, and readers for getting us off to a great start, with its first impact factor of 5.1. academic.oup.com/narcancer - now in our 4th full year of publication!

Discovery, development and molecular basis of defective mismatch repair-mediated immunotherapy: new in our DNA Repair and Therapeutics collection. From Guo-Min Li and Junhong Guan, UTSW Radiation Oncology academic.oup.com/narcancer/arti… #editorschoice #Immunotherapy

Proof of concept for innovative combination therapy for ovarian cancer- now out in NAR Cancer. Read our latest!

Read our latest - exciting work on a new post-transcriptional regulatory mechanism in ER mutant breast cancer!

Read our latest Cancer Data Resource paper: CrypticProteinDB: an integrated database of proteome and immunopeptidome derived non-canonical cancer proteins. From Christopher Maher and ghofran othoum Washington U. Med academic.oup.com/narcancer/arti…

NAR Cancer after 3.5 years, by the numbers: 360 submissions (with 114 transfers from Nucleic Acids Res), 166 articles published, 50 Editorial Board members, 5 Associate Editors, 40% current acceptance rate. Average turnaround time 29 days - students take note! academic.oup.com/narcancer

Roadmap for a next generation therapeutic: Disruption of RAD52–ssDNA complexation via novel drug-like inhibitors. From Maria Spies, PhD (she/her) lab. Congratulations to first author Divya Bhat on her PhD! doi.org/10.1093/narcan…

Excited to announce the publication of my thesis work in NAR Cancer Editor-in-Chief!

Thank you to my mentor Jonathan Brody; this work (and myself!) was supported by Brenden-Colson Center for Pancreatic Care OHSU Department of Surgery and Jefferson Surgery

academic.oup.com/narcancer/arti…
Jen M. Finan Yifei (Miffy) Guo Rosie Sears
#PancreaticCancer

New in NAR Cancer: Metastatic cancer of unknown primary (CUP) traced using DNA methylation-based AI classifier.

Newest editor's choice article: Molecular origins of mutational spectra produced by environmental carcinogen NDMA and Sn1 chemotherapy agents. From Amanda Armco, John Essigmann & colleagues @chemistryMIT #carcinogenesis #ranitidine academic.oup.com/narcancer/arti…

OUP announces plans for a new addition to the NAR journal family: NAR Molecular Medicine. They are seeking an editor in chief at this time.